pSivida completes recruitment of European Pancreatic Cancer Study and releases preliminary findings

15-Aug-2007

pSivida Limited announced the completion of the recruitment stage of the 17 persons Phase IIa clinical study of BrachySilTM for the treatment of inoperable pancreatic cancer at three leading hospitals in the United Kingdom and Singapore. All are major centers for cancer therapy.

Preliminary data are very encouraging. Eight weeks follow-up data available on the first 10 patients treated shows 90% of these patients have had either stabilization or reduction in size of their primary tumor and none of these patients experienced product related significant adverse events. Preliminary data on the balance of the patients treated will be released when a minimum of eight weeks follow-up data have been obtained. The first analysis of all the patients is expected to be available at the end of the calendar year and results will be used to guide future studies.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances